Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.43), $0.46 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $73.5 million versus the consensus estimate of $71.59 million.

“We are very pleased to report another strong quarter, marrying our vision to become one of the most meaningful precision genetic medicine companies globally with a strong focus on execution against both our near- and long-term range goals,” stated Doug Ingram, Sarepta’s president and chief executive officer. “Our robust quarterly sales for EXONDYS 51, increasing patients on therapy and strong adherence and compliance speaks to the benefits of EXONDYS 51 and to our ability as a fully integrated, commercial-stage genetic medicine company to support our therapies in the community and deliver on our commitments. At the same time we took enormous strides in the quarter in the direction of our lofty strategic vision by announcing very positive preliminary results from our first gene therapy program focused on the use of micro-dystrophin to treat Duchenne muscular dystrophy, accelerating the development of our gene therapy center of excellence and enhancing our senior management team with the addition of two scientific leaders, Drs. Gilmore O’Neill and Louise Rodino-Klapac, and advancing our hybrid gene therapy manufacturing strategy with our long-term relationship with gold standard manufacturer, Brammer Bio.”

Mr. Ingram continued, “We have entered into our next gene therapy collaboration, with Lacerta Therapeutics, gaining access to world-leading talent, next-generation tools, and three additional gene therapy programs, one focused on Pompe Disease and two additional CNS-targeted programs, with the purpose of supporting our strategic expansion. Over the remainder of 2018, we have much to do and also numerous catalysts that have the potential to solidify us as a leader in precision genetic medicine and a company focused on rapidly developing therapies to extend and enhance the lives of those living with rare, genetic-based disease.”

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.